IP Library Granted Patent US 7,884,198
Granted Patent B2
US 7,884,198 · App. 12/317,718 · Granted Feb 8, 2011

Polynucleotides encoding humanized and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria

Assignees: The Henry M. Jackon Foundation for the Advancement of Military Medicine; Altor Bioscience Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,884,198
App. No.
12/317,718
Granted
Feb 8, 2011
Kind
B2
Abstract

The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and/or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics.

Claims (12)

1. An isolated polynucleotide encoding a humanized antibody or an antigen-binding fragment thereof having binding specificity to LTA of Gram positive bacteria, the humanized antibody comprising:

(i) a light chain comprising three complementarity determining regions (CDRs) from the immunoglobulin light chain variable region sequence set forth as SEQ ID NO:89, and framework regions from a human acceptor immunoglobulin light chain; and

(ii) a heavy chain comprising three complementarity determining regions (CDRs) from the immunoglobulin heavy chain variable region sequence set forth as SEQ ID NO:87, and framework regions from a human acceptor immunoglobulin heavy chain.

2. An isolated polynucleotide encoding a chimeric antibody comprising the heavy chain variable region sequence set forth as SEQ ID NO:87 and the light chain variable region sequence set forth as SEQ ID NO:89 and human constant regions.

3. An isolated polynucleotide encoding a humanized antibody or an antigen-binding

fragment thereof having binding specificity to LTA of Gram positive bacteria, the humanized antibody comprising:

(i) a light chain comprising three complementarity determining regions (CDRs) from the immunoglobulin light chain variable region sequence set forth as SEQ ID NO:89; and

(ii) a heavy chain comprising three complementarity determining regions (CDRs) from the immunoglobulin heavy chain variable region sequence set forth as SEQ ID NO:87.

4. An isolated polynucleotide encoding a chimeric antibody comprising the heavy chain variable region sequence set forth as SEQ ID NO:87 and the light chain variable region sequence set forth as SEQ ID NO:90 and human constant regions.

5. An isolated vector comprising the polynucleotide of any one of claims 1 - 4 .

6. An isolated cell comprising the polynucleotide of any one of claims 1 - 4 .

7. An isolated cell comprising the vector of claim 5 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2010
From: FISCHER, GERALD W.; SCHUMAN, RICHARD F.
To: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE
Reel/Frame 024353/0995 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2010
From: WONG, HING; STINSON, JEFFREY R.
To: SUNOL MOLECULAR CORPORATION
Reel/Frame 024354/0022 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2010
From: SUNOL MOLECULAR CORPORATION
To: ALTOR BIOSCIENCE CORPORATION
Reel/Frame 024354/0036 →
Continuity (5)
Division 11193440 · Aug 1, 2005
Continuation 10601171 · Jun 23, 2003
Continuation 09097055 · Jun 15, 1998
Provisional Application 60049871 · Jun 16, 1997
Related Publication 20100221822A1 · Sep 2, 2010